SAPIEN 3 China Post Market Registry Study

Patient with symptomatic, severe, calcified aortic stenosis who is appropriate for the treatment with transcatheter aortic valve replacement as determined by a heart team and will undergo TAVI with the Edwards SAPIEN 3 System as part of standard-of-care treatment

All surgical risks as determined by the site Heart Team

The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Medical, social, or psychological conditions that preclude appropriate consent and follow-up, including subjects under guardianship

Considered to be part of a vulnerable population

Pre-existing mechanical or bioprosthetic aortic valve

Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments

Cannot tolerate an anticoagulation/antiplatelet regimen

Evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis

Tortuous or calcified vessels that would prevent safe entry of the dilators and sheath

Participating in a drug or device study that has not reached its primary endpoint